ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
11 hedge funds and large institutions have $15.3M invested in ESSA Pharma in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
924% more capital invested
Capital invested by funds: $1.49M → $15.3M (+$13.8M)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
2.12% more ownership
Funds ownership: 1.19% → 3.31% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
+$6.51M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$4.17M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.12M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.44M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$121 |
EPIX Hedge Fund Activity: Q1 2018 in Review
11 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q1 2018, worth a combined $15.3M — up 924% from $1.49M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EPIX positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Clarus Ventures, adding an estimated $6.51M. The largest seller was Susquehanna International Group, cutting an estimated $11K.
- 11 institutional investors held ESSA Pharma (EPIX) as of Q1 2018, up from 10 in Q4 2017.
- Funds reported $15.3M of ESSA Pharma stock for Q1 2018, up 924% quarter-over-quarter.
- 3 funds opened new ESSA Pharma positions in Q1 2018 and 2 closed out, a net change of +1 holder.
- The largest ESSA Pharma buyer in Q1 2018 was Clarus Ventures, an estimated $6.51M added.
- The largest ESSA Pharma seller in Q1 2018 was Susquehanna International Group, an estimated $11K sold.
Based on aggregated 13F filings for Q1 2018.